Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats

被引:98
作者
Yamashita, A
Yonemitsu, Y
Okano, S
Nakagawa, K
Nakashima, Y
Irisa, T
Iwamoto, Y
Nagai, Y
Hasegawa, M
Sueishi, K
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Div Pathophysiol & Expt Pathol,Higashi Ku, Fukuoka 8128582, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Orthoped Surg, Fukuoka 8128582, Japan
[3] DNAVEC Res, Tsukuba, Ibaraki, Japan
[4] Natl Inst Infect Dis, Ctr AIDS Res, Tokyo, Japan
关键词
D O I
10.4049/jimmunol.168.1.450
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Rheumatoid arthritis (RA), a systemic inflammatory disease of unknown etiology, mainly affects synovial joints. Although angiogenic growth factors, including fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), may play a critical role in the development and progression of RA joint disease, little information is now available regarding their exact role in initiation and/or progression of RA. In this study, we show that both poly peptides were up-regulated in the rat joint synovial tissue of an adjuvant-induced model of arthritis (AIA), as well as human subjects with RA. FGF-2 overexpression via Sendai virus-mediated gene transfer significantly worsened clinical symptoms and signs of rat AIA, including hind paw swelling and radiological bone destruction, as well as histological findings based on inflammatory reaction, synovial angiogenesis, pannus formation, and osteocartilaginous destruction, associated with up-regulation of endogenous VEGF. FGF-2 gene transfer to non-AIA joints was without effect. These findings suggested that FGF-2 modulated disease progression, but did not affect initiation. Reverse experiments using anti-FGF-2-neutralizing rabbit IgG attenuated clinical symptoms and histopathological abnormalities of AIA joints. To our knowledge, this is the first report indicating direct in vivo evidence of disease-modulatory effects of FGF-2 in AIA, as probably associated with endogenous VEGF function. FGF-2 may prove to be a possible therapeutic target to treat subjects with RA.
引用
收藏
页码:450 / 457
页数:8
相关论文
共 48 条
[1]   Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis [J].
Ahrens, D ;
Koch, AE ;
Pope, RM ;
SteinPicarella, M ;
Niedbala, MJ .
ARTHRITIS AND RHEUMATISM, 1996, 39 (09) :1576-1587
[2]  
ARNETT FC, 1987, ARTHRITIS RHEUM, V31, P315
[3]   STUDIES ON THE CHRONIC PHASE OF ADJUVANT ARTHRITIS - EFFECT OF SR-41319, A NEW DIPHOSPHONATE [J].
BARBIER, A ;
BRELIERE, JC ;
REMANDET, B ;
RONCUCCI, R .
ANNALS OF THE RHEUMATIC DISEASES, 1986, 45 (01) :67-74
[4]  
Bullough PG., 1992, Atlas of Orthopedic Pathology with Clinical and Radiological Correlations
[5]  
Chabaud M, 1998, J IMMUNOL, V161, P409
[6]   IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis [J].
Chabaud, M ;
Lubberts, E ;
Joosten, L ;
van den Berg, W ;
Miossec, P .
ARTHRITIS RESEARCH, 2001, 3 (03) :168-177
[7]   Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42/p44 MAP kinase [J].
Chikazu, D ;
Hakeda, Y ;
Ogata, N ;
Nemoto, K ;
Itabashi, A ;
Takato, T ;
Kumegawa, M ;
Nakamura, K ;
Kawaguchi, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (40) :31444-31450
[8]   ANGIOGENESIS AND RHEUMATOID-ARTHRITIS - PATHOGENIC AND THERAPEUTIC IMPLICATIONS [J].
COLVILLENASH, PR ;
SCOTT, DL .
ANNALS OF THE RHEUMATIC DISEASES, 1992, 51 (07) :919-925
[9]   VASCULAR-PERMEABILITY FACTOR ENDOTHELIAL GROWTH-FACTOR (VPF/VEGF) - ACCUMULATION AND EXPRESSION IN HUMAN SYNOVIAL-FLUIDS AND RHEUMATOID SYNOVIAL TISSUE [J].
FAVA, RA ;
OLSEN, NJ ;
SPENCERGREEN, G ;
YEO, KT ;
YEO, TK ;
BERSE, B ;
JACKMAN, RW ;
SENGER, DR ;
DVORAK, HF ;
BROWN, LF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) :341-346
[10]  
Firestein GS, 1996, TXB RHEUMATOLOGY, P851